Clinical Pharmacology & Mechanism of Action
Tesamorelin is a highly potent, FDA-approved synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It consists of the 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid group attached to the N-terminal tyrosine.
This unique hexenoyl modification protects the peptide from rapid degradation by the DPP-4 enzyme in the bloodstream, significantly extending its half-life and potency compared to native GHRH or Sermorelin.
Tesamorelin binds directly to the GHRH receptors in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. Its most clinically significant and unique property is its profound effect on visceral adipose tissue (VAT) - the dangerous, hard fat stored deep in the abdomen around the organs.
In clinical trials, Tesamorelin demonstrated a highly targeted ability to mobilize and burn visceral fat, leading to its FDA approval (under the brand name Egrifta) for the treatment of HIV-associated lipodystrophy .
Pharmacokinetics & Lipodystrophy Research
- Half-life: Roughly 30 to 45 minutes, allowing it to produce a sharp, robust pulse of GH before clearing the system.
- Tissue Specificity: While all GH secretagogues promote lipolysis, Tesamorelin appears uniquely suited to target visceral fat over subcutaneous fat. Researchers hypothesize this is due to how its specific pharmacokinetic profile interacts with the density of GH receptors in deep visceral adipose tissue.
Standard Research Dosing Protocols
Because Tesamorelin is primarily used to radically alter body composition (specifically reducing abdominal girth), the standard dosing protocol is more aggressive than anti-aging peptides like Sermorelin.
- Dosage: 1.0mg to 2.0mg per day.
- Frequency: Administered once daily (often before bed) or split into two 1.0mg doses (morning and night).
- Administration Condition: Strict fasting is required (2 hours post-meal) to prevent insulin from blunting the GH release.
Reconstitution Math & Syringe Guide
Tesamorelin doses are in milligrams (mg), not micrograms, which makes calculating the syringe units slightly different than CJC-1295 or Ipamorelin.
Step-by-Step Reconstitution (10mg Vial)
- Swab the rubber stoppers of your 10mg Tesamorelin vial and your Bacteriostatic Water.
- Using a sterile mixing syringe, draw exactly 2mL of Bacteriostatic Water.
- Inject the water slowly down the inside wall of the Tesamorelin vial.
- Swirl gently. Wait for the solution to become completely clear.
The Math for a Standard Dose (1.0mg):
- 10mg total in the vial.
- You added 2mL of water.
- Therefore, the concentration is 5mg per 1mL.
- You need a 1.0mg dose. Divide the dose by the concentration: 1.0 ÷ 5 = 0.2mL.
- 0.2mL = 20 units on a U-100 syringe.
Note: If you have a 2mg vial and add 1mL of water, the concentration is 2mg/mL. A 1.0mg dose would require 0.5mL (50 units).
Common Mistakes & Troubleshooting
- Confusing mg with mcg: Tesamorelin is dosed in milligrams. A 1.0mg dose is 1,000mcg. Do not attempt to dose it at 100mcg like CJC-1295; you will see zero results.
- Poor Storage: Tesamorelin is known to be slightly less stable in suspension than other peptides. It must be strictly refrigerated and should ideally be used within 14-21 days of reconstitution.
- Site Reactions: Because doses require injecting larger amounts of active peptide (1-2mg), localized redness and itching at the injection site are more common with Tesamorelin than with highly diluted peptides.